159 related articles for article (PubMed ID: 33375410)
1. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Baranov MV; Bianchi F; van den Bogaart G
Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
3. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.
Nelson EA; Dyall J; Hoenen T; Barnes AB; Zhou H; Liang JY; Michelotti J; Dewey WH; DeWald LE; Bennett RS; Morris PJ; Guha R; Klumpp-Thomas C; McKnight C; Chen YC; Xu X; Wang A; Hughes E; Martin S; Thomas C; Jahrling PB; Hensley LE; Olinger GG; White JM
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005540. PubMed ID: 28403145
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.
Kang YL; Chou YY; Rothlauf PW; Liu Z; Soh TK; Cureton D; Case JB; Chen RE; Diamond MS; Whelan SPJ; Kirchhausen T
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20803-20813. PubMed ID: 32764148
[TBL] [Abstract][Full Text] [Related]
5. Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling.
Cinato M; Guitou L; Saidi A; Timotin A; Sperazza E; Duparc T; Zolov SN; Giridharan SSP; Weisman LS; Martinez LO; Roncalli J; Kunduzova O; Tronchere H; Boal F
Theranostics; 2021; 11(13):6491-6506. PubMed ID: 33995670
[No Abstract] [Full Text] [Related]
6. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
[TBL] [Abstract][Full Text] [Related]
7. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
[TBL] [Abstract][Full Text] [Related]
8. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
[TBL] [Abstract][Full Text] [Related]
9. PIKfyve inhibition increases exosome release and induces secretory autophagy.
Hessvik NP; Øverbye A; Brech A; Torgersen ML; Jakobsen IS; Sandvig K; Llorente A
Cell Mol Life Sci; 2016 Dec; 73(24):4717-4737. PubMed ID: 27438886
[TBL] [Abstract][Full Text] [Related]
10. Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
Sultana F; Morse LR; Picotto G; Liu W; Jha PK; Odgren PR; Battaglino RA
J Cell Biochem; 2020 Apr; 121(4):2927-2937. PubMed ID: 31692073
[TBL] [Abstract][Full Text] [Related]
11. PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19.
Logue J; Chakraborty AR; Johnson R; Goyal G; Rodas M; Taylor LJ; Baracco L; McGrath ME; Haupt R; Furlong BA; Soong M; Prabhala P; Horvath V; Carlson KE; Weston S; Ingber DE; DePamphilis ML; Frieman MB
Commun Biol; 2022 Aug; 5(1):808. PubMed ID: 35962188
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
13. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research.
Rihn SJ; Merits A; Bakshi S; Turnbull ML; Wickenhagen A; Alexander AJT; Baillie C; Brennan B; Brown F; Brunker K; Bryden SR; Burness KA; Carmichael S; Cole SJ; Cowton VM; Davies P; Davis C; De Lorenzo G; Donald CL; Dorward M; Dunlop JI; Elliott M; Fares M; da Silva Filipe A; Freitas JR; Furnon W; Gestuveo RJ; Geyer A; Giesel D; Goldfarb DM; Goodman N; Gunson R; Hastie CJ; Herder V; Hughes J; Johnson C; Johnson N; Kohl A; Kerr K; Leech H; Lello LS; Li K; Lieber G; Liu X; Lingala R; Loney C; Mair D; McElwee MJ; McFarlane S; Nichols J; Nomikou K; Orr A; Orton RJ; Palmarini M; Parr YA; Pinto RM; Raggett S; Reid E; Robertson DL; Royle J; Cameron-Ruiz N; Shepherd JG; Smollett K; Stewart DG; Stewart M; Sugrue E; Szemiel AM; Taggart A; Thomson EC; Tong L; Torrie LS; Toth R; Varjak M; Wang S; Wilkinson SG; Wyatt PG; Zusinaite E; Alessi DR; Patel AH; Zaid A; Wilson SJ; Mahalingam S
PLoS Biol; 2021 Feb; 19(2):e3001091. PubMed ID: 33630831
[TBL] [Abstract][Full Text] [Related]
14. PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron.
Acharya A; Pathania AS; Pandey K; Thurman M; Vann KR; Kutateladze TG; Challagundala KB; Durden DL; Byrareddy SN
Clin Transl Med; 2022 Apr; 12(4):e806. PubMed ID: 35390226
[No Abstract] [Full Text] [Related]
15. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
Ribone SR; Paz SA; Abrams CF; Villarreal MA
J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
[TBL] [Abstract][Full Text] [Related]
16. The Lipid Kinase PIKfyve Coordinates the Neutrophil Immune Response through the Activation of the Rac GTPase.
Dayam RM; Sun CX; Choy CH; Mancuso G; Glogauer M; Botelho RJ
J Immunol; 2017 Sep; 199(6):2096-2105. PubMed ID: 28779020
[TBL] [Abstract][Full Text] [Related]
17. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
Kuo CJ; Chao TL; Kao HC; Tsai YM; Liu YK; Wang LH; Hsieh MC; Chang SY; Liang PH
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526482
[TBL] [Abstract][Full Text] [Related]
18.
Umadevi P; Manivannan S; Fayad AM; Shelvy S
J Biomol Struct Dyn; 2022 Jul; 40(11):5053-5059. PubMed ID: 33372574
[No Abstract] [Full Text] [Related]
19. Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control.
Wible DJ; Parikh Z; Cho EJ; Chen MD; Jeter CR; Mukhopadhyay S; Dalby KN; Varadarajan S; Bratton SB
Cell Death Dis; 2024 Jan; 15(1):80. PubMed ID: 38253602
[TBL] [Abstract][Full Text] [Related]
20. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
Billich A
IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
